{"title_page": "5F-ADBICA", "text_new": "{{Drugbox\n| IUPAC_name = ''N''-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1''H''-indole-3-carboxamide \n| image = 5F-ADBICA_structure.png\n\n<!--Clinical data-->\n| tradename =  \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B            / C / D / X -->\n| pregnancy_category =  \n| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->\n| legal_CA = Schedule II\n| legal_DE = NpSG\n| legal_UK = PSA\n| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->\n| legal_status =\n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability =  \n| protein_bound =  \n| metabolism =  \n| elimination_half-life =  \n| excretion =\n\n<!--Identifiers-->\n| CAS_number_Ref = \n| CAS_number = 1801338-27-1\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = U9H280G9O7\n| ATC_prefix = \n| ATC_suffix = \n| PubChem = \n| ChemSpiderID = 29342128\n\n<!--Chemical data-->\n| C=20 | H=28 | N=3 | O=2 | F=1\n| molecular_weight = 361.46 g/mol\n| smiles = FCCCCCn1cc(c2c1cccc2)C(=O)NC(C(C)(C)C)C(=O)N\n| StdInChI = 1S/C20H28FN3O2/c1-20(2,3)17(18(22)25)23-19(26)15-13-24(12-8-4-7-11-21)16-10-6-5-9-14(15)16/h5-6,9-10,13,17H,4,7-8,11-12H2,1-3H3,(H2,22,25)(H,23,26)\n| StdInChIKey = ITZSOCZDFSHNCL-UHFFFAOYSA-N\n}}\n\n'''5F-ADBICA''' (also known as '''5F-ADB-PICA''') is an [[indole]]-based [[synthetic cannabinoid]] that is a potent [[agonist]] at [[CB1 receptor|CB<sub>1</sub> receptors]] and [[CB2 receptor|CB<sub>2</sub> receptors]] with EC<sub>50</sub> values of 0.77 nM and 1.2 nM respectively.<ref>{{cite journal | title=The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA | author=Samuel D Banister | author2=Michael Moir | author3=Jordyn Stuart| author4=Richard C Kevin | author5=Katie E Wood| author6=Mitchell Longworth | author7=Shane M Wilkinson| author8=Corinne Beinat | author9=Alxendra S Buchanan| author10=Michelle Glass | author11=Mark Connor| author12=Iain S McGregor | author13=Michael Kassiou | journal=ACS Chemical Neuroscience |date=July 2015  | doi=10.1021/acschemneuro.5b00112 | pmid=26134475 | volume=6 |issue = 9| pages=1546\u201359}}</ref><ref>{{cite web | url=http://forendex.southernforensic.org/index.php/detail/index/1262 | title=5F-ADBICA | publisher=Southern Association of Forensic Scientists | accessdate=21 July 2015 | archive-url=https://web.archive.org/web/20150927090554/http://forendex.southernforensic.org/index.php/detail/index/1262 | archive-date=27 September 2015 | url-status=dead | df=dmy-all }}</ref>\n\n==Legal Status==\n\n===China===\nAs of October 2015 5F-ADBICA is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=\u5173\u4e8e\u5370\u53d1\u300a\u975e\u836f\u7528\u7c7b\u9ebb\u9189\u836f\u54c1\u548c\u7cbe\u795e\u836f\u54c1\u5217\u7ba1\u529e\u6cd5\u300b\u7684\u901a\u77e5 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>\n\n==See also==\n{{div col|colwidth=30em}}\n* [[ADBICA]]\n* [[ADB-PINACA]]\n* [[APICA (synthetic cannabinoid drug)|APICA]]\n* [[PX-1]]\n* [[SDB-001]]\n* [[STS-135 (drug)|STS-135]]\n{{Div col end}}\n\n==References==\n<references/>\n\n{{Cannabinoids}}\n\n[[Category:Cannabinoids]]\n[[Category:Designer drugs]]\n[[Category:Indolecarboxamides]]\n\n\n{{cannabinoid-stub}}\n", "text_old": "{{Drugbox\n| IUPAC_name = ''N''-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1''H''-indole-3-carboxamide \n| image = 5F-ADBICA_structure.png\n\n<!--Clinical data-->\n| tradename =  \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B            / C / D / X -->\n| pregnancy_category =  \n| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->\n| legal_CA = Schedule II\n| legal_DE = NpSG\n| legal_UK = PSA\n| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->\n| legal_status =\n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability =  \n| protein_bound =  \n| metabolism =  \n| elimination_half-life =  \n| excretion =\n\n<!--Identifiers-->\n| CAS_number_Ref = \n| CAS_number = 1801338-27-1\n| ATC_prefix = \n| ATC_suffix = \n| PubChem = \n| ChemSpiderID = 29342128\n\n<!--Chemical data-->\n| C=20 | H=28 | N=3 | O=2 | F=1\n| molecular_weight = 361.46 g/mol\n| smiles = FCCCCCn1cc(c2c1cccc2)C(=O)NC(C(C)(C)C)C(=O)N\n| StdInChI = 1S/C20H28FN3O2/c1-20(2,3)17(18(22)25)23-19(26)15-13-24(12-8-4-7-11-21)16-10-6-5-9-14(15)16/h5-6,9-10,13,17H,4,7-8,11-12H2,1-3H3,(H2,22,25)(H,23,26)\n| StdInChIKey = ITZSOCZDFSHNCL-UHFFFAOYSA-N\n}}\n\n'''5F-ADBICA''' (also known as '''5F-ADB-PICA''') is an [[indole]]-based [[synthetic cannabinoid]] that is a potent [[agonist]] at [[CB1 receptor|CB<sub>1</sub> receptors]] and [[CB2 receptor|CB<sub>2</sub> receptors]] with EC<sub>50</sub> values of 0.77 nM and 1.2 nM respectively.<ref>{{cite journal | title=The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA | author=Samuel D Banister | author2=Michael Moir | author3=Jordyn Stuart| author4=Richard C Kevin | author5=Katie E Wood| author6=Mitchell Longworth | author7=Shane M Wilkinson| author8=Corinne Beinat | author9=Alxendra S Buchanan| author10=Michelle Glass | author11=Mark Connor| author12=Iain S McGregor | author13=Michael Kassiou | journal=ACS Chemical Neuroscience |date=July 2015  | doi=10.1021/acschemneuro.5b00112 | pmid=26134475 | volume=6 |issue = 9| pages=1546\u201359}}</ref><ref>{{cite web | url=http://forendex.southernforensic.org/index.php/detail/index/1262 | title=5F-ADBICA | publisher=Southern Association of Forensic Scientists | accessdate=21 July 2015 | archive-url=https://web.archive.org/web/20150927090554/http://forendex.southernforensic.org/index.php/detail/index/1262 | archive-date=27 September 2015 | url-status=dead | df=dmy-all }}</ref>\n\n==Legal Status==\n\n===China===\nAs of October 2015 5F-ADBICA is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=\u5173\u4e8e\u5370\u53d1\u300a\u975e\u836f\u7528\u7c7b\u9ebb\u9189\u836f\u54c1\u548c\u7cbe\u795e\u836f\u54c1\u5217\u7ba1\u529e\u6cd5\u300b\u7684\u901a\u77e5 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>\n\n==See also==\n{{div col|colwidth=30em}}\n* [[ADBICA]]\n* [[ADB-PINACA]]\n* [[APICA (synthetic cannabinoid drug)|APICA]]\n* [[PX-1]]\n* [[SDB-001]]\n* [[STS-135 (drug)|STS-135]]\n{{Div col end}}\n\n==References==\n<references/>\n\n{{Cannabinoids}}\n\n[[Category:Cannabinoids]]\n[[Category:Designer drugs]]\n[[Category:Indolecarboxamides]]\n\n\n{{cannabinoid-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/5F-ADBICA"}
